{"id":{"repo_id":"msu","oai_identifier":"oai:d.lib.msu.edu:etd_3893"},"canonical_url":"https://search.ndltd.org/etd/msu/oai:d.lib.msu.edu:etd_3893","repository":{"repo_id":"msu","name":"Michigan State University","base_url":"https://d.lib.msu.edu/oai"},"display":{"title":"Treatment of autism spectrum disorder within a Medicaid-enrolled pediatric sample : prevalence and predictors of psychopharmacological treatment","abstract":"The purpose of this study was to contribute to the literature on the prevalence of psychotropic medications for youth with autism spectrum disorder within a sample of Medicaid-enrolled children and adolescents (N = 8,058) in the state of Michigan in the year 2009. Prevalence of psychopharmacological treatments, rates of polypharmacy, and the predictive value of participant, educational, and healthcare characteristics were analyzed. Results indicated that 60% of participants were prescribed a psychotropic medication, and approximately 36% received polypharmacy intervention. Older age, identifying as White, having an Asperger’s diagnosis, and receiving a comorbid diagnosis were found to be associated with an increased likelihood of being prescribed psychopharmacologic intervention. County educational characteristics, specifically total number of students and student-teacher ratio, were also found to influence psychopharmacologic prescribing. Lastly, a dramatic increase in prevalence rates was identified between 2001 (32%) and 2009 (60%) for youth with autism spectrum disorder. In summary, psychopharmacologic prevalence doubled during the targeted decade in the state of Michigan, and variables outside of the scope of medical best practice were found to influence psychopharmacologic prescribing practices. Implications of study findings on future research are discussed.","abstract_html":"The purpose of this study was to contribute to the literature on the prevalence of psychotropic medications for youth with autism spectrum disorder within a sample of Medicaid-enrolled children and adolescents (N = 8,058) in the state of Michigan in the year 2009. Prevalence of psychopharmacological treatments, rates of polypharmacy, and the predictive value of participant, educational, and healthcare characteristics were analyzed. Results indicated that 60% of participants were prescribed a psychotropic medication, and approximately 36% received polypharmacy intervention. Older age, identifying as White, having an Asperger’s diagnosis, and receiving a comorbid diagnosis were found to be associated with an increased likelihood of being prescribed psychopharmacologic intervention. County educational characteristics, specifically total number of students and student-teacher ratio, were also found to influence psychopharmacologic prescribing. Lastly, a dramatic increase in prevalence rates was identified between 2001 (32%) and 2009 (60%) for youth with autism spectrum disorder. In summary, psychopharmacologic prevalence doubled during the targeted decade in the state of Michigan, and variables outside of the scope of medical best practice were found to influence psychopharmacologic prescribing practices. Implications of study findings on future research are discussed.","abstract_has_math":false,"creators":["Ham, Hannah L."],"institution":null,"degree_name":null,"degree_level":null,"degree_discipline":null,"degree_department":null,"school":null,"contributors":["Carlson, John","Witmer, Sara","Volker, Martin","Magen, Jed","Michigan State University"],"advisors":[],"committee_chairs":[],"committee_members":[],"year":2016,"date_issued":"2016","date_published":"2016","updated_at":"2026-11-18T18:41:46Z","subjects":["Autism spectrum disorders--Treatment","Child mental health","Children with autism spectrum disorders","Medicaid beneficiaries","Psychotropic drugs"],"languages":["English"],"rights":["In Copyright"],"rights_urls":[],"identifier_entries":[{"key":"dc:identifier","label":"Identifier","values":["etd:3893","isbn:9781339730349","isbn:1339730340","oclc:961277536","umi:10109765","local:Ham_grad.msu_0128D_14545"],"render_values":[{"text":"etd:3893","href":null,"code":true},{"text":"isbn:9781339730349","href":null,"code":true},{"text":"isbn:1339730340","href":null,"code":true},{"text":"oclc:961277536","href":null,"code":true},{"text":"umi:10109765","href":null,"code":true},{"text":"local:Ham_grad.msu_0128D_14545","href":null,"code":true}]}],"person_identifier_entries":[]},"links":{"outbound_url":"https://doi.org/doi:10.25335/mn5b-av03","outbound_label":"DOI","outbound_source":"dc:identifier","record_url":"https://doi.org/doi:10.25335/mn5b-av03","record_label":"Repository record","record_kind":"doi","record_source":"dc:identifier","download_url":null,"download_label":null,"download_source":null,"access_status":null,"embargo_until":null,"access_note":null},"source_record":{"url":"https://d.lib.msu.edu/oai?verb=GetRecord&metadataPrefix=oai_dc&identifier=oai%3Ad.lib.msu.edu%3Aetd_3893","prefix":"oai_dc"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:contributor","label":"Contributor","values":["Carlson, John","Witmer, Sara","Volker, Martin","Magen, Jed","Michigan State University"]},{"key":"dc:creator","label":"Author","values":["Ham, Hannah L."]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:coverage","label":"Dc Coverage","values":["Michigan"]},{"key":"dc:date","label":"Dc Date","values":["2016"]},{"key":"dc:relation","label":"Dc Relation","values":["Electronic Theses & Dissertations"]},{"key":"dc:type","label":"Dc Type","values":["Text","Theses"]}]},{"id":"subjects_keywords","label":"Subjects and Keywords","entries":[{"key":"dc:subject","label":"Dc Subject","values":["Autism spectrum disorders--Treatment","Child mental health","Children with autism spectrum disorders","Medicaid beneficiaries","Psychotropic drugs"]}]},{"id":"language_rights","label":"Language and Rights","entries":[{"key":"dc:language","label":"Dc Language","values":["English"]},{"key":"dc:rights","label":"Dc Rights","values":["In Copyright"]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier","label":"Identifier","values":["etd:3893","isbn:9781339730349","isbn:1339730340","oclc:961277536","umi:10109765","local:Ham_grad.msu_0128D_14545","https://doi.org/doi:10.25335/mn5b-av03"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description","label":"Description","values":["The purpose of this study was to contribute to the literature on the prevalence of psychotropic medications for youth with autism spectrum disorder within a sample of Medicaid-enrolled children and adolescents (N = 8,058) in the state of Michigan in the year 2009. Prevalence of psychopharmacological treatments, rates of polypharmacy, and the predictive value of participant, educational, and healthcare characteristics were analyzed. Results indicated that 60% of participants were prescribed a psychotropic medication, and approximately 36% received polypharmacy intervention. Older age, identifying as White, having an Asperger’s diagnosis, and receiving a comorbid diagnosis were found to be associated with an increased likelihood of being prescribed psychopharmacologic intervention. County educational characteristics, specifically total number of students and student-teacher ratio, were also found to influence psychopharmacologic prescribing. Lastly, a dramatic increase in prevalence rates was identified between 2001 (32%) and 2009 (60%) for youth with autism spectrum disorder. In summary, psychopharmacologic prevalence doubled during the targeted decade in the state of Michigan, and variables outside of the scope of medical best practice were found to influence psychopharmacologic prescribing practices. Implications of study findings on future research are discussed.","Thesis (Ph. D.)--Michigan State University. School Psychology, 2016","Includes bibliographical references (pages 152-163)"]},{"key":"dc:format","label":"Dc Format","values":["vii, 163 pages","application/pdf"]},{"key":"dc:title","label":"Title","values":["Treatment of autism spectrum disorder within a Medicaid-enrolled pediatric sample : prevalence and predictors of psychopharmacological treatment"]}]}],"canonical_facts":{"dc:contributor":["Carlson, John","Witmer, Sara","Volker, Martin","Magen, Jed","Michigan State University"],"dc:coverage":["Michigan"],"dc:creator":["Ham, Hannah L."],"dc:date":["2016"],"dc:description":["The purpose of this study was to contribute to the literature on the prevalence of psychotropic medications for youth with autism spectrum disorder within a sample of Medicaid-enrolled children and adolescents (N = 8,058) in the state of Michigan in the year 2009. Prevalence of psychopharmacological treatments, rates of polypharmacy, and the predictive value of participant, educational, and healthcare characteristics were analyzed. Results indicated that 60% of participants were prescribed a psychotropic medication, and approximately 36% received polypharmacy intervention. Older age, identifying as White, having an Asperger’s diagnosis, and receiving a comorbid diagnosis were found to be associated with an increased likelihood of being prescribed psychopharmacologic intervention. County educational characteristics, specifically total number of students and student-teacher ratio, were also found to influence psychopharmacologic prescribing. Lastly, a dramatic increase in prevalence rates was identified between 2001 (32%) and 2009 (60%) for youth with autism spectrum disorder. In summary, psychopharmacologic prevalence doubled during the targeted decade in the state of Michigan, and variables outside of the scope of medical best practice were found to influence psychopharmacologic prescribing practices. Implications of study findings on future research are discussed.","Thesis (Ph. D.)--Michigan State University. School Psychology, 2016","Includes bibliographical references (pages 152-163)"],"dc:format":["vii, 163 pages","application/pdf"],"dc:identifier":["etd:3893","isbn:9781339730349","isbn:1339730340","oclc:961277536","umi:10109765","local:Ham_grad.msu_0128D_14545","https://doi.org/doi:10.25335/mn5b-av03"],"dc:language":["English"],"dc:relation":["Electronic Theses & Dissertations"],"dc:rights":["In Copyright"],"dc:subject":["Autism spectrum disorders--Treatment","Child mental health","Children with autism spectrum disorders","Medicaid beneficiaries","Psychotropic drugs"],"dc:title":["Treatment of autism spectrum disorder within a Medicaid-enrolled pediatric sample : prevalence and predictors of psychopharmacological treatment"],"dc:type":["Text","Theses"]},"updated_at":"2026-11-18T18:41:46Z"}